Cabotegravir 600 mg/3 mL, 30 mg Suppliers & Bulk Manufacturers

Available Forms: Injection/ Tablet

Available Strengths: 600 mg/3 mL, 30 mg

Reference Brands: Apretude (USA), Vocabria (USA)

Category: Critical Care

Cabotegravir 30 mg tablets and 600 mg/3 mL long-acting injectable suspension, an HIV integrase inhibitor for PrEP and treatment. For importers, distributors, HIV programmes and tender buyers.

Product Description:

Cabotegravir is an HIV-1 integrase strand transfer inhibitor: it blocks the enzyme that inserts viral DNA into the host genome. This page covers two forms with different jobs. The 30 mg tablet is a short oral lead-in to check tolerability, or a bridge over a planned missed injection. The 600 mg/3 mL extended-release injectable suspension goes deep into the gluteal muscle and releases drug over weeks, so people need an injection every one or two months instead of daily pills.

For pre-exposure prophylaxis, cabotegravir alone is given to HIV-negative adults and adolescents at risk of sexually acquired HIV: two initiation injections a month apart, then one every two months. WHO guidelines include it as an additional PrEP option. For treatment, it is paired with long-acting rilpivirine in people with suppressed virus. A negative HIV test is needed before each PrEP injection, because undiagnosed infection risks resistance. Levels can persist a year or more. Rifampicin, rifapentine, carbamazepine and phenytoin are contraindicated.

Sourcing notes. Cabotegravir is prescription-only and is often bought through national HIV programmes, whose tenders set the specification. The suspension comes in a single-dose vial with a kit for gluteal injection; confirm its contents. The cabotegravir-only vial needs no refrigeration under its US label, but rilpivirine co-packs need 2-8 °C, so keep the two clearly apart. Ask for a CoA per batch, sterility and particle size data, the GMP certificate, a CoPP and a CTD or ACTD dossier. For donor-funded supply, check WHO prequalification or stringent authority approval first.